Working… Menu

Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04015076
Recruitment Status : Recruiting
First Posted : July 10, 2019
Last Update Posted : July 18, 2019
Information provided by (Responsible Party):
Inflazome UK Ltd

Brief Summary:
This is a first in human (FIH), single-centre, double blind, randomised, cross-over, SAD followed by a MAD study of Inzomelid. The study is designed to evaluate the safety, tolerability, PK, PD, and food effect of Inzomelid in healthy adult participants. Oversight will be provided by a safety monitoring committee (SMC) comprised of the Investigator, the Sponsor's Medical Monitor and an Independent Medical Monitor.

Condition or disease Intervention/treatment Phase
Healthy Drug: Inzomelid Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Other
Official Title: A Phase 1, Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Inzomelid in Healthy Adult Participants
Actual Study Start Date : July 16, 2019
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Arm Intervention/treatment
Experimental: Single Ascending Dose
Inzomelid or Placebo
Drug: Inzomelid
Active Drug

Drug: Placebo
Placebo to Match

Experimental: Multiple Ascending Dose
Inzomelid or Placebo
Drug: Inzomelid
Active Drug

Drug: Placebo
Placebo to Match

Primary Outcome Measures :
  1. Incidence of treatment emergent advert events [Safety and Tolerability] [ Time Frame: Day 1-8 for SAD, Day 1-16 for MAD ]
    Incidence, frequency and severity of treatment emergent advert events

  2. Peak Plasma Concentration (Cmax)-single dose [ Time Frame: Day 1-3 ]
    Peak plasma concentration following single dose administration

  3. Area under the plasma concentration versus time curve (AUC)- single dose [ Time Frame: Day 1-3 ]
    AUC following single dose administration

  4. Peak Plasma Concentration (Cmax)-multiple dose [ Time Frame: Days 1-9 ]
    Peak plasma concentration following multiple dose administration

  5. Area under the plasma concentration versus time curve (AUC)- multiple dose [ Time Frame: Days 1-9 ]
    AUC following multiple dose administration

Secondary Outcome Measures :
  1. Pharmacodynamic activity [ Time Frame: Day 1-3 for SAD and Day 1-9 for MAD ]
    NLRP3 Inhibition in whole blood

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male or female volunteers, aged 18 to 65 years (inclusive at the time of informed consent);
  • Participants must be in good general health, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of study drug;
  • Participants must have a Body Mass Index (BMI) between ≥18.0 and ≤32.0 kg/m2 at Screening;

Exclusion Criteria:

  • Pregnant or lactating at Screening or planning to become pregnant (self or partner) at any time during the study, including the follow-up period;
  • Prior or ongoing medical conditions, medical history, physical findings, or laboratory abnormality that, in the Investigator's (or delegate's) opinion, could adversely affect the safety of the participant;
  • Presence of any underlying physical or psychological medical condition that, in the opinion of the Investigator, would make it unlikely that the participant will comply with the protocol or complete the study per protocol;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04015076

Layout table for location contacts
Contact: Jeff Thompson, PhD, MBA +44(0)1223 751549
Contact: Thomas Jung, MD, PhD +44(0)1223 751549

Layout table for location information
Australia, Queensland
Nucleus Network Recruiting
Melbourne, Queensland, Australia
Contact: Ben Snyder, MB BS         
Sponsors and Collaborators
Inflazome UK Ltd
Layout table for investigator information
Principal Investigator: Ben Snyder, MB, BS Nucleus Network

Layout table for additonal information
Responsible Party: Inflazome UK Ltd Identifier: NCT04015076     History of Changes
Other Study ID Numbers: IZD174-001
First Posted: July 10, 2019    Key Record Dates
Last Update Posted: July 18, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No